Endo to acquire US generics player for $1.2 billion
This article was originally published in Scrip
Executive Summary
Endo Pharmaceuticals is to acquire the "sixth largest generics company in the US", the privately held Qualitest Pharmaceuticals, for around $1.2 billion in cash.